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PARTNER (Placement of Aortic Transcatheter Valve Trial)
remains the only randomized-controlled trial to compare trans-
catheter aortic valve implantation (TAVI) with surgical aortic valve
replacement (AVR) for patients with severe aortic stenosis (1–3).
The survival, symptomatic, and cost benefits of TAVI compared to
medical therapy in inoperable patients has been previously dem-
onstrated (2,4). However, optimal treatment for “high-risk” pa-
tients remains controversial, and there is conflicting evidence on
the cost-effectiveness of TAVI compared to AVR in different
healthcare settings.
Reynolds et al. (5) should be commended on their economic
evaluation of TAVI versus AVR based on a modified intention-
to-treat cohort of 647 patients from the PARTNER A trial, which
represents the first cost analysis to separately assess the transfemo-
ral (TF) and transapical (TA) approaches. Results of this study
reported that the entire TAVI cohort did not demonstrate signif-
icant differences in cost-effectiveness compared with AVR. How-
ever, when stratified according to access site, patients who under-
went the TF approach were more likely to be economically
attractive compared with AVR than the TA approach. This
finding partially reflects the “transfemoral-first” patient selection
process utilized in a number of institutions. Compared with the
TF group, the TA group had increased comorbidities, which
translated into higher perioperative mortality and morbidity and
therefore reduced cost-effectiveness.
Some limitations of this study should be discussed. Firstly,
major bleeding is known to be more likely after AVR than TAVI,
and has been emphasized in the study. However, complications
that are more likely to be associated with TAVI, such as stroke,
atrioventricular block necessitating pacemaker, significant aortic
regurgitation, and conversion to AVR, were not closely examined
(6). Secondly, the assumption that TAVI is performed in the
catheterization laboratory setting for the TF approach may not be
applicable to centers where TAVI is performed in hybrid theaters,
which is often the case in institutions learning this procedure.
Most importantly, the cost-effectiveness of TAVI compared with
AVR is largely dependent on the cost and duration of postopera-
tive hospitalization. It has been shown that patients who undergo
surgery have a longer length of hospitalization compared with
TAVI, and this increase in cost largely offsets the more expensive
cost of the TAVI valve device. For patients who underwent AVR
in the PARTNER trial, the mean hospitalization was 16 days,
which was comparatively longer than other studies involvinghigh-risk candidates (7). In addition, the cost of hospitalization is
much higher in the United States compared with other countries,
favoring the cost benefit of TAVI. This was demonstrated by Neyt
et al. (8) and Osnabrugge et al. (9), who reported incremental
cost-effectiveness ratio (ICER) values of US$975,697 and
US$232,128 in Belgium and the Netherlands, respectively, com-
pared with US$76,877 reported by Reynolds et al. (5).
In conclusion, Reynolds et al. (5) provided insightful data that
ompared TF and TA approaches of TAVI with AVR. However,
ollow-up was relatively short at 12 months and a number of
omplications associated with TAVI might have been neglected.
heir findings were based on the American healthcare system and
ay be less applicable to other countries. Nation-specific economic
ssessments should be performed in the future and a systematic
eview of the cost-effectiveness of TAVI may be warranted.
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Reply
As Dr. Cao and colleagues point out, our recently published
cost-effectiveness analysis, based on patient-level data from the
PARTNER (Placement of Aortic Transcatheter Valves Trial) (1)
has some important limitations. Our analysis used a 12-month
timeframe. From a health economic perspective, this analytic
timeframe is similar to an analysis that assumes that long-term
outcomes between study groups will be comparable. Although
there is presently no empirical evidence suggesting otherwise, this
remains an unproven assumption, which we explicitly noted in the
manuscript.
Also correctly noted was the fact that hospital length of stay
(LOS) was shorter after transcatheter aortic valve replacement
(TAVR) than after surgical aortic valve replacement (AVR),
and the savings associated with reduced LOS play a key role in
offsetting the higher acquisition cost of a transcatheter valve.
The LOS following surgical AVR in the PARTNER trial was
indeed long—about 6 days longer than average LOS for AVR
for all U.S. patients (2). We believe the long LOS after surgical
AVR in the PARTNER trial was primarily related to the
unique risk profile of the patient population, who represent the
highest 5% to 8% risk of patients operated on for aortic stenosis
in the United States. Based on recent publications, it is clear
that “high-risk” patients who currently undergo TAVR in other
countries tend to be lower risk than those who were studied in
the PARTNER A trial. For example, the SOURCE-XT registry
f 2,700 consecutive patients undergoing TAVR in 17 countries
nrolled patients with a mean Society of Thoracic Surgeons (STS)
ortality risk of 8.5% (4) whereas the PARTNER trial population
ad a mean STS mortality risk of 11.8% (3). Moreover, as we
oted in our discussion, even for similar patients, clinical results
nd resource utilization patterns may differ across healthcare
ystems. We agree that country-specific analyses are needed, but
e are concerned about conclusions reached by comparing non-
andomized groups (5). In the absence of randomization, careful
isk adjustment is required to reach balanced conclusions.
Finally, it is not correct to state that our analysis ignored or
eglected complications associated with TAVR. For the TAVR
nd AVR groups in the trial, we measured costs for index and
ollow-up hospitalizations primarily by collecting and analyzing
ospital bills from the enrolling centers. Thus, while we have not
et reported the excess costs associated with specific complications,
hose costs were incorporated into analysis through the 12-month
imeframe of the study.
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Diagnosis of Heart Failure With
Preserved Ejection Fraction
Still a Challenge
Campbell et al. (1) addressed a key issue of heart failure with
preserved ejection fraction (HFPEF). Does it really exist? They
concluded that it does, because of the differences in outcomes,
comorbidities, and biomarkers between hypertensive and HF-
PEF patients in clinical trials. When these studies were carried
out, the performance of diagnostic criteria for HFPEF was
poor. These criteria were omitted from the latest guidelines of
the European Society of Cardiology (ESC). Diagnosis of
HFPEF relies more on left ventricular mass and left atrial size
(2) than on the signs of diastolic dysfunction. The study fails to
discuss whether the majority of patients included in clinical
trials actually had HFPEF. Our view is that inclusion of
patients with a clinical picture similar to HF—termed the
EXIT (EXercise InTolerance) syndrome (3)—may account for
the observed differences. Ingle et al. (4) showed that a propor-
tion of patients diagnosed with HFPEF actually had another
entity, clinically similar to HF, with lower B-type natriuretic
peptide concentrations and a better prognosis. Among exercise-
intolerant patients, age, comorbidities, atrial fibrillation, obe-
sity, deconditioning, and unexpected degrees of renal dysfunc-
tion might play an important role. This might explain why
sensitive markers of glomerular filtration rate, such as cystatin
C, perform so well in patients with HFPEF (5). Almeida et al.
(6) showed that patients with acutely decompensated HFPEF,
who fulfilled the ESC diagnostic criteria had a worse prognosis,
comparable to HF and a reduced ejection fraction (HFREF).
These data suggested an exercise-intolerance syndrome, similar
to HFPEF, with a better prognosis—a factor that could have
distorted the results of HFPEF clinical trials and might account
for the differences in prognosis between HFPEF and HFREF.
We consider HFPEF to be a reality, although doubts as to its
clinical profile and diagnostic criteria still persist beyond the
conclusions of the study by Campbell et al. (1). The challenge
is to identify them without the need for complex assessments.
